Agenus (AGEN)
(Delayed Data from NSDQ)
$4.68 USD
+0.02 (0.43%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $4.68 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.68 USD
+0.02 (0.43%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $4.68 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Zacks News
Agenus (AGEN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of -89.47% and 63.68%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
AC Immune (ACIU) delivered earnings and revenue surprises of -159.52% and 99.17%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Agenus (AGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Agenus (AGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Awaits Biogen (BIIB) in Q2 Earnings Post Leqembi Setback?
by Zacks Equity Research
Biogen's (BIIB) sales in the second quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been hurt by increased competition.
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical
by Zacks Equity Research
Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical are part of the Zacks top Analyst Blog.
Biotech Stock Roundup: SAGE Plunges on Study Failure, AGEN Down on Regulatory Update & More
by Ekta Bagri
Sage Therapeutics (SAGE) and Agenus (AGEN) are in the spotlight following study failure and regulatory updates, respectively.
What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?
by Zacks Equity Research
Structure Therapeutics (GPCR) is expected to provide updates on the developmental pathway of its lead product candidate, GSBR-1290, for diabetes and obesity indications in the Q2 earnings release.
Geron (GERN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Geron (GERN) is expected to primarily provide updates regarding the launch of its newly approved hematologic malignancy drug, Rytelo, in the United States when it reports second-quarter earnings.
Agenus (AGEN) Tanks on Colorectal Cancer Study Interim Data
by Zacks Equity Research
The FDA rejects the accelerated approval pathway for Agenus' (AGEN) BOT/BAL combination in relapsed/refractory microsatellite stable colorectal cancer patients.
IGM Biosciences (IGMS) Soars 32.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
IGM Biosciences (IGMS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) reports mixed first-quarter results. Management reiterates the 2024 financial outlook.
Agenus (AGEN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of 15.08% and 31.19%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Agenus (AGEN) Soars 6.8%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Agenus (AGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
IGM Biosciences, Inc. (IGMS) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 4.72% and 31.47%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Milestone Pharma (MIST) Down on Regulatory Update for Etripamil
by Zacks Equity Research
Milestone Pharma (MIST) plunges 31% following an RTF letter from the FDA due to insufficient data to begin a substantive review of the regulatory filing for etripamil nasal spray to treat PSVT.
Merck (MRK) & Daiichi Sankyo's Lung Cancer ADC Gets Priority Tag
by Zacks Equity Research
Merck (MRK) and Daiichi Sankyo's regulatory filing for HER3-DXd gets the FDA's priority review grant for the treatment of adult patients with lung cancer. A final decision is expected on Jun 26, 2024.
GSK, Hansoh Ink Deal to Develop Lung Cancer ADC Candidate
by Zacks Equity Research
GSK enters into an exclusive licensing agreement with China-based Hansoh to develop and commercialize the latter's lung cancer candidate, HS-20093.
Immunovant (IMVT) Up on Upbeat Initial Batoclimab GD Study Data
by Zacks Equity Research
Immunovant (IMVT) announces positive initial data from the mid-stage study of batoclimab in patients with Graves' disease. The stock gains 12% in the after-market hours, following the news.
CARA's Late-Stage Skin Disease Study Fails, Stock Plummets 49%
by Zacks Equity Research
CARA discontinues the clinical program of oral difelikefalin for pruritus associated with atopic dermatitis following the failure of dose-finding Part A of the late-stage study. Stock plunges 49%.
Reneo (RPHM) Plummets 83% on Failure of Metabolic Disorder Study
by Zacks Equity Research
Reneo (RPHM) loses 83% following the failure of the mid-stage pivotal study of its only pipeline candidate, mavodelpar, to treat primary mitochondrial myopathies in adults. It cuts the workforce by 70%.
Acadia (ACAD) Rises 35% on Positive Patent Ruling for Nuplazid
by Zacks Equity Research
Acadia (ACAD) announces a ruling from the U.S. District Court in Delaware, strongly in favor of the company for its patent for Nuplazid. The stock surges 35% in response.
Blueprint (BPMC) Gets EC Nod for Ayvakit Expanded Use, Stock Up
by Zacks Equity Research
Blueprint (BPMC) announces EC approval expanding Ayvakit's indication to include the treatment of adult patients with indolent systemic mastocytosis. The stock gained 5%.
Biomea Fusion (BMEA) Stock Surges 41% in a Month: Here's Why
by Zacks Equity Research
Biomea Fusion (BMEA) rises 41% in a month on the back of positive investor expectations regarding the clinical development of its lead candidate, BMF-219, for the type II diabetes indication.
Century (IPSC) Up 36% on FDA Nod to Begin Phase I Lupus Study
by Zacks Equity Research
Century (IPSC) set to begin early-stage study on lead product candidate, CNTY-101, for treatment of systemic lupus erythematosus following IND clearance by FDA. The stock rises 36%.
Dr. Reddy's (RDY), COYA Ink Deal to Develop COYA 302 for ALS
by Zacks Equity Research
Dr. Reddy's (RDY) enters into a licensing agreement with Coya Therapeutics to develop and commercialize the latter's ALS investigational combination therapy, COYA 302.